RNatives’ Co-founder and Chief Scientific Officer to give Keynote Presentation at Cell & Gene Therapy Summit
Mikko Turunen to present on the company’s RNA-based gene regulating platform, RNAIntel
Kuopio, Finland and Boston, USA – July 7, 2025 – RNatives, Inc., a biotechnology company developing precision RNA-based gene regulating therapies to treat serious diseases, announced that its co-founder and Chief Scientific Officer, Mikko Turunen, PhD, will give a keynote presentation today at the Cell & Gene Therapy Summit 2025 in Orlando, Florida.
Mikko Turunen’s presentation will focus on the company’s novel RNA-based gene regulating platform, RNAIntel, which utilizes artificial intelligence and machine learning to identify small non-coding RNAs that regulate gene expression. “Current RNA therapies have generally ignored nuclear non-coding RNAs,” said Turunen. “Our RNAIntel platform is uniquely capable of identifying specific small RNAs that precisely target nuclear non-coding RNAs to activate or silence genes.”
RNatives is leveraging the extraordinary potential of its RNAIntel platform to develop precision RNA therapies to address currently untreatable rare and common ocular and metabolic diseases, as well as cancer.
###
About RNatives
RNatives is a biotechnology company developing precision RNA-based gene regulating therapies to treat serious diseases by leveraging its RNAIntel platform, which identifies small non-coding RNAs that regulate gene expression. The Company is developing novel RNA-based therapies to treat ocular and metabolic diseases, as well as cancer.
Media Contacts:
RNatives
Jeff Abbey, CEO